
Lyxor AM adds Caxton HAWK quant strategy to Dimension UCITS platform
Lyxor Asset Management this week announced the launch of its third alternative single manager on its Lyxor Dimension UCITS platform.

Lyxor Asset Management this week announced the launch of its third alternative single manager on its Lyxor Dimension UCITS platform.
Hong Kong-based Samena Asia Managers (SAM), the hedge fund seeding arm of Samena Capital, has entered into a joint venture with Geneva-headquartered Reyl &

KB Associates, the boutique operational consultancy firm, this week announc

SPDR ETFs, the ETF platform of State Street Global Advisors (SSgA), announced this week that it had launched the SPDR Barclays EM Inflation-Linked Local Bond UCITS ETF on the Deutsche Borse; the world’s first ETF to offer pure exposure to
Jupiter Asset Management is to dispense with hedge funds altogether as a separate business line as it prepares to switch investors into regulated vehicles reported FINalternatives this week,

Online& has launched its tiered website platform designed specifically to assist companies in the alternative investment community enhance their marketing, investor relations, regulatory compliance, and data security efforts. With flexible pricing and no ongoing subscription costs, the solution scales to

NYSE Liffe, the Europe-based derivatives business of NYSE Euronext (NYX) is adding options on the shares in UNIT4 N.V. (ticker symbol: UNT) to its highly successful range of equity option classes. Trading in options on UNIT4 will start on 24
ITG, an independent execution and research broker, has launched a new hosted solution for ITG Order Management System (formerly known as Macgregor XIP). This new web-based solution offers a cost-effective alternative to traditional OMS deployments for use by both

London-based Prodigy Capital Partners is initiating plans to restructure and redomicile its Prodigy Asia & Emerging Markets fund from the Cayman Islands to Luxembourg it said in a shareh
The Securities and Exchange Commission has charged a former hedge fund portfolio manager with insider trading in a bio-pharmaceutical company based on confidential information about negative results of the company’s clinical drug trial. The SEC alleges that Dr Joseph F